CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 60 filers reported holding CYTOSORBENTS CORP in Q1 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $348,329 | +23.8% | 185,282 | +136.3% | 0.00% | 0.0% |
| Q2 2023 | $281,465 | +6.7% | 78,409 | +0.2% | 0.00% | – |
| Q1 2023 | $263,707 | +124.3% | 78,256 | +3.3% | 0.00% | – |
| Q4 2022 | $117,550 | +16.4% | 75,727 | +1.3% | 0.00% | – |
| Q3 2022 | $101,000 | -39.2% | 74,767 | -1.4% | 0.00% | – |
| Q2 2022 | $166,000 | -89.2% | 75,867 | +1.2% | 0.00% | -100.0% |
| Q1 2022 | $1,541,000 | +390.8% | 74,935 | +0.2% | 0.00% | +200.0% |
| Q4 2021 | $314,000 | -49.6% | 74,750 | -2.4% | 0.00% | 0.0% |
| Q3 2021 | $623,000 | +6.0% | 76,558 | -1.5% | 0.00% | 0.0% |
| Q2 2021 | $588,000 | -8.0% | 77,750 | +5.7% | 0.00% | -50.0% |
| Q1 2021 | $639,000 | +7.6% | 73,550 | -1.1% | 0.00% | 0.0% |
| Q4 2020 | $594,000 | +37.8% | 74,400 | +37.8% | 0.00% | +100.0% |
| Q3 2020 | $431,000 | +12.8% | 54,010 | +40.1% | 0.00% | 0.0% |
| Q2 2020 | $382,000 | +35.9% | 38,560 | -12.3% | 0.00% | 0.0% |
| Q1 2020 | $281,000 | – | 43,980 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $846,000 | 0.90% |
| Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
| Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
| Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
| Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
| Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
| HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
| Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
| Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |